Analysts on Wall Street project that BioMarin Pharmaceutical (BMRN) will announce quarterly earnings of $0.57 per share in its forthcoming report, representing an increase of 5.6% year over year. Revenues are projected to reach $660.51 million, increasing 11% from the same quarter last year. While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a ...

Now Approved for Children of All Ages with CLN2 Batten Disease, Regardless of Whether They Yet Show Symptoms The sBLA is supported by data from Study 190-203, a Phase 2, open-label, multicenter trial evaluating BRINEURA treatment over the span of approximately three years in children aged 1-6 years at baseline, including eight children less than 3 years of age. Results from Study 190-203, which were presented at the 20th Annual We're Organizing Research on Lysosomal Diseases meeting (WORLDSymposium) in Febr ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering BioMarin Pharmaceutical (BMRN) , which belongs to the Zacks Medical - Biomedical and Genetics industry. For the last reported quarter, BioMarin came out with earnings of $0.71 per share versus the Zacks Consensus Estimate of $0.60 per share, representing a surprise of 18.33%. For the previous quarter, the company was expected to post earnings of $0.44 per sha ...

SAN RAFAEL, Calif., July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, August 5, 2024, at 4:30 p.m. ET to discuss second quarter 2024 financial results and provide a general business update. Contacts: Investors Media Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc.BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 Dial-in Number U.S ...

BioMarin Pharmaceutical (BMRN) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, th ...

Investors in BioMarin Pharmaceutical (BMRN) need to pay close attention to the stock based on moves in the options market lately. That is because the Sept 20, 2024 $40.00 Call had some of the highest implied volatility of all equity options today. What do the Analysts Think? Given the way analysts feel about BioMarin Pharmaceutical right now, this huge implied volatility could mean there's a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium ...

SAN RAFAEL, Calif., May 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President, and Chief Executive Officer of BioMarin will present at the BofA Securities 2024 Healthcare Conference on Wednesday, May 15, 2024, at 10:00am PT / 1:00pm ET, in Las Vegas, Nevada. An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through ...

As we near the end of the ongoing reporting cycle in the biotech sector, the picture is pretty ho-hum. The bigwigs in the sector have already reported and the results have been mostly mixed. Nonetheless, the outlook provided by most of these companies is encouraging, indicating bright prospects driven by new drug approvals and positive pipeline updates. The macroeconomic environment, however, remains uncertain and growth might be sluggish.Nonetheless, companies in this volatile biotech industry continue to ...

Investigator-Sponsored Phase 2 Study Demonstrated Positive Results in Children with Noonan Syndrome, Idiopathic Short Stature and Other Growth-Related Conditions BioMarin-Sponsored Phase 3 Data Show Notable Mean Annualized Growth Velocity Increases in Children with Achondroplasia Who Started Treatment During Adolescence SAN RAFAEL, Calif., May 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive new data supporting the safety and efficacy of VOXZOGO® (vosoritide) in ch ...

| --- | --- | |-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...